FibriCheck and Smart Meter are now collaborating to bring remote heart health monitoring to U.S. patients. This partnership supports healthcare providers with insights into critical heart rhythm data for improved clinical decision-making. This integration can be scaled into remote patient…
HASSELT - February 21, 2025 - Digital health pioneers Inhealthcare and FibriCheck today announced the expansion of their partnership to bring hospital-grade heart monitoring into patients' homes through NHS virtual ward pathways. Inhealthcare has developed more than 150 clinically designed…
FibriCheck entered the U.S. market with FDA-approved heart monitoring technology 2024 was a transformative year for FibriCheck as we achieved FDA clearance (K232804) for our entire ecosystem, including our patient-facing app, AI-powered algorithm, and healthcare provider portal. The FDA-clearance allows…
Digital health innovators FibriCheck and patientMpower are joining forces to help transform the management of cardiovascular conditions, thereby saving lives, reducing health inequalities and easing pressure on the healthcare system. A joint approach to improve the outcomes of cardiac conditions …
We have added a new feature to FibriCheck that has been designed in order to support healthcare providers with their patient follow-up. Healthcare providers will now be able to log treatments (e.g. ablation, cardioversion, and medication) or diagnostics (e.g. Holter…
We are committed to continuous innovation and enhancement of our product features to improve remote heart health monitoring. To provide deeper insights into risk factors for heart conditions, we have integrated a weight logging functionality into FibriCheck. This new functionality…
10 years ago, we set out as pioneers with a bold vision: to empower individuals and healthcare providers with an innovative tool that could detect heart rhythm disorders using nothing more than a smartphone. Today, as we celebrate ten years…
After a rigorous investigation procedure by the Food and Drug Administration, FibriCheck is now FDA-cleared (K232804). This is an important milestone which supports our further development in the U.S. market. The FDA-clearance allows us to improve current U.S. care pathways…
Cardiovascular disease is the leading cause of mortality worldwide, placing a significant strain on healthcare systems. The growing amount of people needing care causes workforce shortages, financial constraints, and lengthy hospital waitlists which may put people at risk of complications…
At FibriCheck, we believe that the best way to improve our services to our users and to make advancements in a fast-paced world is by never ceasing to explore new opportunities and by finding innovative ways to get the most…